Carchman S H, Crowe J T, Wright G J
A. H. Robins Company, Department of Drug Metabolism, Richmond, VA 23220.
J Clin Pharmacol. 1987 Oct;27(10):762-7. doi: 10.1002/j.1552-4604.1987.tb02993.x.
Guanfacine is a centrally acting alpha-2 adrenergic agonist. The absolute bioavailability, pharmacokinetics, and renal clearance of this antihypertensive drug were investigated in healthy male volunteers. Eighteen subjects received a single oral or intravenous dose of guanfacine 3 mg in a two-way cross-over study design. Blood samples were obtained before dosing and up to 72 hours after dosing for determination of drug levels in plasma. Additional blood samples were obtained for protein binding studies. Urine was collected and pooled for specific intervals up to 96 hours after dosing. The absolute bioavailability of guanfacine after a single oral dose was 81.1%. The elimination half-lives were 13.8 hours and 13.4 hours after oral and intravenous administration, respectively. The volume of distribution results were approximately 6 L/kg by both routes of administration. The mean plasma protein binding results were 71.6%, not influenced by plasma concentration or route of administration. The urinary recovery of guanfacine was 44.3% after oral dosing and 50% after intravenous dosing. Renal clearance of guanfacine was 50% of total body clearance and appeared to be due to a net renal tubular secretory process.
胍法辛是一种中枢作用的α-2肾上腺素能激动剂。在健康男性志愿者中研究了这种抗高血压药物的绝对生物利用度、药代动力学和肾清除率。在一项双向交叉研究设计中,18名受试者接受了单次口服或静脉注射3毫克胍法辛。在给药前和给药后长达72小时采集血样,以测定血浆中的药物水平。采集额外的血样用于蛋白质结合研究。在给药后长达96小时的特定时间段内收集尿液并合并。单次口服给药后胍法辛的绝对生物利用度为81.1%。口服和静脉给药后的消除半衰期分别为13.8小时和13.4小时。两种给药途径的分布容积结果均约为6升/千克。平均血浆蛋白结合率结果为71.6%,不受血浆浓度或给药途径的影响。口服给药后胍法辛的尿回收率为44.3%,静脉给药后为50%。胍法辛的肾清除率占全身清除率的50%,似乎是由于肾小管净分泌过程所致。